# Molecular Basis of Phosphatidyl-myo-inositol Mannoside Biosynthesis and Regulation in Mycobacteria

Marcelo E. Guerin, Jana Korduláková, Pedro M. Alzari, Patrick J. Brennan,

Mary Jackson

► To cite this version:

Marcelo E. Guerin, Jana Korduláková, Pedro M. Alzari, Patrick J. Brennan, Mary Jackson. Molecular Basis of Phosphatidyl-myo-inositol Mannoside Biosynthesis and Regulation in Mycobacteria. Journal of Biological Chemistry, 2010, 285 (44), pp.33577-33583. 10.1074/jbc.R110.168328. pasteur-03137935

HAL Id: pasteur-03137935

https://pasteur.hal.science/pasteur-03137935

Submitted on 10 Feb 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Molecular Basis of Phosphatidyl-
*myo*-inositol Mannoside
*Biosynthesis and Regulation
*in Mycobacteria*\*

Published, JBC Papers in Press, August 27, 2010, DOI 10.1074/jbc.R110.168328

Marcelo E. Guerin<sup>+5¶1</sup>, Jana Korduláková<sup>‡</sup>, Pedro M. Alzari<sup>**</sup>, Patrick J. Brennan<sup>††</sup>, and Mary Jackson<sup>††2</sup>

From the<sup>†</sup>Unidad de Biofísica, Centro Mixto Consejo Superior de Investigaciones Científicas-Universidad del País Vasco/Euskal Herriko Unibertsitatea (CSIC-UPV/EHU), Barrio Sorriena s/n, Leioa, Bizkaia 48940, Spain, the<sup>§</sup>Departamento de Bioquímica, Universidad del País Vasco, 48940 País Vasco, Spain, <sup>¶</sup>IKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Spain, the<sup>||</sup>Department of Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynská Dolina, 84215 Bratislava, Slovakia, the <sup>**</sup>Unité de Biochimie Structurale, CNRS URA 2185, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, and the <sup>††</sup>Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado 80523-1682

Phosphatidyl-*myo*-inositol mannosides (PIMs) are unique glycolipids found in abundant quantities in the inner and outer membranes of the cell envelope of all *Mycobacterium* species. They are based on a phosphatidyl-*myo*-inositol lipid anchor carrying one to six mannose residues and up to four acyl chains. PIMs are considered not only essential structural components of the cell envelope but also the structural basis of the lipoglycans (lipomannan and lipoarabinomannan), all important molecules implicated in host-pathogen interactions in the course of tuberculosis and leprosy. Although the chemical structure of PIMs is now well established, knowledge of the enzymes and sequential events leading to their biosynthesis and regulation is still incomplete. Recent advances in the identification of key proteins involved in PIM biogenesis and the determination of the three-dimensional structures of the essential phosphatidyl-*myo*-inositol mannosyltransferase PimA and the lipoprotein LpqW have led to important insights into the molecular basis of this pathway.

*myo*-Inositol, as a phospholipid constituent, was first reported in mycobacteria by R. J. Anderson in 1930 (1). Subsequently, the presence of phosphatidyl-*myo*-inositol (PI)<sup>3</sup> dim-

annosides (PIM<sub>2</sub>) and PI pentamannosides (PIM<sub>5</sub>) was recognized in *Mycobacterium tuberculosis* (2, 3). Over the past 40 years, the structure of the complete family of PI mannosides (PIM<sub>1</sub>–PIM<sub>6</sub>) in various *Mycobacterium* spp. and related Actinomycetes has been defined, first as deacylated glycerophosphoryl-*myo*-inositol mannosides and later as the fully acylated native molecules (4).

PIMs and metabolically related lipoglycans comprising lipo-mannan (LM) and lipoarabinomannan (LAM) are nonvalently anchored through their PI moiety to the inner and outer membranes of the cell envelope (5, 6) and play various essential although poorly defined roles in mycobacterial physiology. They are also thought to be important virulence factors during the infection cycle of *M. tuberculosis*. Aided by the availability of a growing number of genome sequences from lipoglycan-producing Actinomycetes, developments in the genetic manipulation of these organisms, and advances in our understanding of the molecular processes underlying sugar transfer in Corynebacterianae, considerable progress was made over the last 10 years in identifying the enzymes associated with the biogenesis of PIM, LM, and LAM (for recent review, see Refs. 7 and 8). The precise chemical definition of these molecules from various Actinomycetes combined with comparative analyses of their interactions with the host immune system also has shed light on their structure-function relationships (9).

In this minireview, we present some key enzymatic, structural, and topological aspects of the biogenesis of PIMs, a pathway that may represent a paradigm for that of other mycobacterial complex (glyco)lipids. The elucidation of this pathway has helped in our understanding of the pathogenesis of tuberculosis and revealed new opportunities for drug discovery.

## Chemical Structure of PIMs: An Overview

The PIM family of glycolipids comprises PI mono-, di-, tri-, tetra-, penta-, and hexamannosides with different degrees of acylation. PIM<sub>2</sub> and PIM<sub>6</sub> are the two most abundant classes found in *Mycobacterium bovis* bacillus Calmette-Guérin (BCG), *M. tuberculosis* H37Rv, and *Mycobacterium smegmatis* 607 (10). The presence of *myo*-inositol and mannose as sugar constituents of phospholipids from *M. tuberculosis* was first reported by Anderson in the 1930s (1, 11–13). Using similar approaches 25 years later, Lee and Ballou arrived at a complete structure of PIM<sub>2</sub> from *M. tuberculosis* and *Mycobacterium phlei* and provided evidence of the existence of mono-, tri-, tetra-, and pentamannoside variants (2, 3, 14, 15). A reanalysis of PIMs from *M. smegmatis* in their deacylated form later revealed a structure based on that previously defined by Ballou *et al*. but containing six Man<sup>p</sup> residues (PIM<sub>6</sub>) (16). The complete chemical structures of the acylated native forms of PIM<sub>2</sub> and PIM<sub>6</sub> were later reinvestigated in *M. bovis* BCG and

<footnote>* This work was supported, in whole or in part, by National Institutes of Health Grants R01 AI064798 and R37 AI018357 from NIAID. This work was also supported by IKERBASQUE, the Basque Foundation for Science, the Fundacion Biofísica Bizkaia, European Commission Contract LSHP-CT-2005-018923 (New Medicines for Tuberculosis), and the Infectious Disease SuperCluster (Colorado State University). This minireview will be reprinted in the 2010 Minireview Compendium, which will be available in January, 2011.</footnote>

<footnote>This work is dedicated to Professor Clinton E. Ballou, honoring the precise and definitive research on the structures of the phosphatidylinositol mannosides conducted by him and his colleagues during the 1960s.</footnote>

<footnote n="1">¹ To whom correspondence may be addressed. E-mail: mrcguerin@gmail.com.</footnote>

<footnote n="2">² To whom correspondence may be addressed. E-mail: mary.jackson@colstate.edu.</footnote>

<footnote n="3">³ The abbreviations used are: PI, phosphatidyl-*myo*-inositol; PIM<sub>1</sub>, PI mono-mannoside; PIM<sub>2</sub>, PI dimannoside; PIM<sub>3</sub>, PI trimannoside; PIM<sub>4</sub>, PI tetra-</footnote>

<footnote>mannoside; PIM<sub>5</sub>, PI pentamannoside; PIM<sub>6</sub>, PI hexamannoside; LM, lipo-mannan; LAM, lipoarabinomannan; BCG, bacillus Calmette-Guérin; α-ManT, α-mannosyltransferase; GT, glycosyltransferase.</footnote>
<figure><img src="image_2.png" /><figcaption>FIGURE 1. Proposed model for PIM biosynthesis and regulation. A, chemical structure of PIM. One Manp residue (in beige) is attached to position 2 of *myo*-inositol (in red), whereas the total number of Manp residues attached to position 6 may range from zero to five. In PIM₂, the *myo*-inositol ring is glycosylated with a Manp unit at each of positions 2 and 6 (beige). In PIM₄, a dimannosyl unit, *t*-α-Manp(1→6)-α-Manp(1→6) (yellow), further extends the Manp linked to position 6 of the *myo*-inositol ring of PIM₂. PIM₆ results from the elongation of PIM₄ by the diman-nosyl unit *t*-α-Manp(1→2)-α-Manp(1→2) (orange). AcylT, acyltransferase; n.d., not determined. B, topology model for the biosynthesis of PIMs, LM, and LAM in mycobacteria. See text for details. The precise identity of the PIM intermediate(s) translocated from the cytosolic to the periplasmic side of the plasma membrane, whether (Ac₁,₂)PIM₂, (Ac₁/₂)PIM₃, or (Ac₁/₂)PIM₄, remains to be determined. The biosynthesis of PIMs takes place on both sides of the inner membrane. Synthesis is initiated on the cytoplasmic side, where Manp is transferred from GDP-Manp to PI, followed by one to three additional Manp residues. On the periplasmic side, the mannolipid is extended by addi-tional Manp residues up to PIM₆. The enzymes involved belong to the GT-C fold family of GTs, which are predicted to have between 8 and 13 transmembrane α-helices with the active site located on an extracytoplasmic loop. Subse-quent mannosylation and arabinosylation steps in LM and LAM biosynthesis (light blue, Manp residues; dark blue, Araf residues; white, Manp-capping residues) are thought to all take place on the periplasmic side of the plasma membrane, requiring polyprenyl-phosphate-sugar donors. As an important part of the literature on the biosynthe-sis of PIM, LM, and LAM refers to the *M. tuberculosis* H37Rv genes, the Rv numbers of the proteins required for the different catalytic steps of the pathway are indicated. The *M. tuberculosis* CDC1551 nomenclature was used in the case of *pimC* (*MT1800*), as this gene lacks an ortholog in H37Rv.</figcaption></figure>

unequivocally established (Fig. 1A) (10, 17). PIM₂ is composed of two Manp residues attached to positions 2 and 6 of the *myo*-inositol ring of PI. PIM₆ is composed of a pentamannosyl group, *t*-α-Manp(1→2)-α-Manp(1→2)-α-Manp(1→6)-α-Manp(1→6)-α-Manp(1→), attached to position 6 of the *myo*-inositol ring, in addition to the Manp residue present at position 2 (Fig. 1A). Brennan and Ballou (18) initially found that PIM₂ occurs in multiple acylated forms, where two fatty acids are attached to the glycerol moiety, and two additional fatty

acids may esterify available hydroxyls on the Manp residue and/or the *myo*-inositol ring (Fig. 1A). The tri- and tetraacylated forms of PIM₂ and PIM₆ (Ac₁PIM₂/Ac₂PIM₂ and Ac₁PIM₆/Ac₂PIM₆) are the most abundant. Ac₁PIM₂ and Ac₁PIM₆ from *M. bovis* BCG show major acyl forms containing two palmitic acid residues (C16) and one tubercu-lostearic acid residue (10-methyl-octadecanoate, C19), where one fatty acyl chain is linked to the Manp residue attached to position 2 of *myo*-inositol, and two fatty acyl chains are located on the glycerol moiety. The tetraacylated forms, Ac₂PIM₂ and Ac₂PIM₆, are present pre-dominantly as two populations bearing either three C16/one C19 or two C16/two C19 (10, 17). Mass spectrometry analyses have led to the conclusion that the glycerol moiety is preferentially acylated with C16/C19. Other acylation po-sitions are C3 of the *myo*-inositol unit and C6 of Manp linked to C2 of *myo*-inositol.

Suggestive of a metabolic relationship, the reducing end of LM and LAM shares structural similarities with PIMs in that the *myo*-inositol residues of the PI of PIMs, LM, and LAM are mannosylated at positions 2 and 6, and similar fatty acyl chains esterify the glycerol moiety, Manp linked to C2 of *myo*-inositol, and the *myo*-inositol ring (16, 19–21).

## PIM₂ Biosynthesis

Ac₁PIM₂ and Ac₂PIM₂ are considered both metabolic end products and intermediates in the biosynthesis of Ac₁PIM₆/Ac₂PIM₆, LM, and LAM. According to the currently accepted model, PIM synthesis is initiated by the transfer of two Manp residues and one fatty

acyl chain onto PI on the cytosolic face of the plasma membrane. The first step consists of the transfer of a Manp residue from GDP-Manp to position 2 of the *myo*-inositol ring of PI to form PI monomannoside (PIM₁) (Fig. 1, A and B) (15). On the basis of genetic, enzymatic, and structural evidence, we identified PimA from *M. smegmatis* (orthologous to Rv2610c of *M. tuberculosis* H37Rv) as the α-mannosyltransferase (*α*-ManT) responsible for this catalytic step and found this enzyme to be essential for the growth of *M. smegmatis* mc²¹⁵⁵
and *M. tuberculosis* (22, 23).<fnref n="4" /> The second step involves the action of the α-ManT PimB' (Rv2188c), also an essential enzyme of *M. smegmatis*, which transfers a Manp residue from GDP-Manp to position 6 of the *myo*-inositol ring of PIM₁ (23, 24). The essential character of both PimA and PimB' validates these enzymes as therapeutic targets worthy of further development.

Both PIM₁ and PIM₂ can be acylated with palmitate at position 6 of the Manp residue transferred by PimA by the acyl-transferase Rv2611c to form Ac₁PIM₁ and Ac₁PIM₂, respectively. The disruption of *Rv2611c* abolishes the growth of *M. tuberculosis* and severely alters that of *M. smegmatis* particularly at low NaCl concentrations and when detergent (Tween 80) is present in the culture medium (25).<fnref n="4" /> Based on cell-free assays, two models were originally proposed for the biosynthesis of Ac₁PIM₂ in mycobacteria. In the first model, PI is mannosylated to form PIM₁. PIM₁ is then further mannosylated to form PIM₂, which is acylated to form Ac₁PIM₂. In the second model, PIM₁ is first acylated to Ac₁PIM₁ and then mannosylated to Ac₁PIM₂. Recent cell-free assays using pure enzymes alone or in combination with *M. smegmatis* membrane extracts indicated that although both pathways might co-exist in mycobacteria, the sequence of events PI → PIM₁ → PIM₂ → Ac₁PIM₂ is favored (23). The acyltransferase responsible for the transfer of a fourth acyl group to position 3 of the *myo*-inositol ring has not yet been identified.

A major advance in our understanding of the molecular basis of the biosynthesis of the PIM₂ family was provided by the structural characterization of PimA from *M. smegmatis* mc²¹⁵⁵ (26). PimA is not only a key player in the biosynthetic pathway of PIM but also a paradigm of a large family of peripheral membrane-associated glycosyltransferases (GTs), the molecular mechanisms of substrate/membrane recognition and catalysis of which are poorly understood. The PimA enzyme, which belongs to the ubiquitous GT4 family of retaining GTs (CAZy (Carbohydrate-Active enZYMes) Database), displays the typical GT-B fold of GTs (Fig. 2A) (26, 27). The crystal structure of a PimA·GDP-Manp complex revealed that the enzyme adopts a "closed" conformation in the presence of GDP-Manp, with the GDP moiety of the sugar donor substrate making binding interactions predominantly with the C-terminal domain of the protein (Fig. 2B). The three-dimensional structure also provided clear insights into the architecture of the lipid acceptor-binding site. Docking calculations and site-directed mutagenesis validated the position of the polar head of the lipid acceptor, *myo*-inositol phosphate, in a well defined pocket with its O₂ atom favorably positioned to receive the Manp residue from GDP-Manp (Fig. 2B) (28).

More recently, experimental evidence based on structural, calorimetric, mutagenesis, and enzyme activity studies indicated that PimA undergoes significant conformational changes upon substrate binding that seem to be important for catalysis. Specifically, the binding of the donor substrate, GDP-Manp, triggered an important interdomain rearrangement from an "open" to a closed state that stabilized the enzyme and consid-

erably enhanced its affinity for the acceptor substrate, PI. The interaction of PimA with the β-phosphate of GDP-Manp was essential for this conformational change to occur. The open-to-closed motion brings together critical residues from the N- and C-terminal domains, allowing the formation of a functionally competent active site. In contrast, the binding of PI to the enzyme had the opposite effect, inducing the formation of a more relaxed complex with PimA. It could be speculated that PI binding allows the initiation of the enzymatic reaction and induces the "opening" of the protein, allowing the product to be released. Interestingly, GDP-Manp stabilized and PI destabilized PimA by a similar enthalpic amount, suggesting that they form or disrupt an equivalent number of interactions within PimA complexes. Altogether, our experimental data support a model wherein flexibility and conformational transitions confer upon PimA the adaptability to the donor and acceptor substrates required for catalysis (28). In this regard, PimA thus seems to follow an ordered mechanism similar that reported for other GT-B enzymes (29, 30).

Another key aspect of the mode of action of PimA is its interaction with membranes. To perform their biochemical functions, membrane-associated GTs interact with membranes by two different mechanisms. Whereas integral membrane GTs are permanently attached through transmembrane regions (e.g. hydrophobic α-helices) (31), peripheral membrane-associated GTs temporarily bind membranes by (i) a stretch of hydrophobic residues exposed to bulk solvent, (ii) electropositive surface patches that interact with acidic phospholipids (e.g. amphipathic α-helices), and/or (iii) protein-protein interactions (32–35). A close interaction of the α-ManTs PimA and PimB' with membranes is likely to be a strict requirement for PI/PIM modification. Consistent with this hypothesis, the membrane association of PimA via electrostatic interactions is suggested by the presence of an amphipathic α-helix and surface-exposed hydrophobic residues in the N-terminal domain of the protein (Fig. 2B). Despite the fact that sugar transfer is catalyzed between the mannosyl group of the GDP-Manp donor and the *myo*-inositol ring of PI, the enzyme displayed an absolute requirement for both fatty acid chains of the acceptor substrate in order for the transfer reaction to take place. Most importantly, although PimA was able to bind monodisperse PI, its transferase activity was stimulated by high concentrations of non-substrate anionic surfactants, indicating that the reaction requires a lipid-water interface (26). Interestingly, critical residues and their interactions are preserved in PimA and PimB', strongly supporting conserved catalytic and membrane association mechanisms (23).

## Biosynthesis of PIM₅, PIM₆, LM, and LAM

Ac₁PIM₂ and Ac₂PIM₂ can be further elongated with additional Manp residues to form higher PIM species (such as Ac₁PIM₃–Ac₁PIM₆/Ac₂PIM₃–Ac₂PIM₆), LM, and LAM (Fig. 1B). It has been proposed that the third Manp residue of PIM is added to Ac₁PIM₂ by the nonessential GDP-Manp utilizing α-ManT PimC, identified in the genome of *M. tuberculosis* CDC1551 (36). However, this enzyme is absent from other mycobacterial genomes (e.g. *M. smegmatis* and *M. tuberculosis* H37Rv), suggesting the existence of an alternative pathway.

<figure><img src="image_3.png" /></figure>

<footnote n="4">⁴ N. Barilone, G. Stadthagen, and M. Jackson, unpublished data.</footnote>
<figure><img src="image_4.png" /><figcaption>FIGURE 2. **Structural basis of PimA and LpqW.** A, overall structure of PimA. The enzyme (42.3 kDa; shown in A and B in its closed conformation) displays the typical GT-B fold of GTs, consisting of two Rossmann fold domains with a deep fissure at the interface that includes the catalytic center. Met¹–Gly¹⁶⁹ and Trp³⁴⁹–Ser³⁷³ form the N-terminal domain of the protein (in *yellow*), whereas the C-terminal domain consists of Val¹⁷⁰–Asp³⁴⁸ (in *orange*). The core of each domain is composed of seven parallel β-strands alternating with seven connecting α-helices. Two regions of the structure have poor or no</figcaption></figure>

Likewise, the α-ManT (PimD) that catalyzes the transfer of the fourth Manp residue onto PI trimannosides remains to be identified. Ac₁PIM₄/Ac₂PIM₄ seems to be a branch point intermediate in Ac₁PIM₆/Ac₂PIM₆ and LM/LAM biosynthesis. The addition of two α-1,2-linked Manp residues to Ac₁PIM₄/Ac₂PIM₄, a combination not found in the mannan backbone of LM and LAM, leads to the formation of the higher order mannosides Ac₁PIM₆ and Ac₂PIM₆ (31, 37, 38). PimE (Rv1159) has been recently identified as an α-1,2-ManT involved in the biosynthesis of higher order PIMs. PimE belongs to the GT-C superfamily of GTs, which comprises integral membrane proteins that use polyprenyl-linked sugars as donors (7, 8, 27, 31). A combination of phenotypic characterization of *M. tuberculosis* and *M. smegmatis* pimE knock-out mutants and cell-free assays clearly indicated that PimE transfers a Manp residue from poly- prenol-phosphate-mannose to Ac₁PIM₄ to form Ac₁PIM₅ at the periplasmic face of the plasma membrane (Fig. 1, A and B) (31).⁴ The α-1,2-ManT responsible for the formation of PIM₆ from PIM₅ is not yet known.

A screening for *M. smegmatis* transposon mutants with defects in cell envelope synthesis led to the discovery of a mutant harboring an insertion in the putative lipoprotein-encoding gene *lpqW* (orthologous to *Rv1166* of *M. tuberculosis* H37Rv). On complex media, the mutant formed small colonies that produced much reduced quantities of LAM compared with the wild-type parent strain. This phenotype was unstable, however, as the mutant rapidly evolved to give rise to variants that had restored LAM biosynthesis but failed to produce higher PIMs and accumulated the branch point intermediate Ac₁PIM₄ (39). Consistent with the accumulation of this intermediate, the restoration of LAM synthesis in the *lpqW* mutant was accounted for by secondary mutations in the *pimE* gene affecting the extracytoplasmic enzyme activity of this protein (40). From these findings, it was proposed that LpqW is required to channel PIM₄ into LAM synthesis (Fig. 1B) and that loss of PimE, which results in the accumulation of high levels of Ac₁PIM₄ in the cells, bypasses the need for LpqW (40). The crystal structure of LpqW (41) revealed an overall fold (Fig. 2C)

electron density, indicating conformational flexibility. The conserved connecting loop β3-α2 (residues 59-70) within the N-terminal domain and the C-terminal extension of the protein (residues 374-386) that is missing in other mycobacterial PimA homologs is shown as dashed lines. B, model of action for PimA. See text for details. The secondary structure of a selected region of PimA (in a different orientation than in A) including the GDP-Manp (GDM)- and myo-inositol phosphate (IP)-binding sites and the amphipathic α2 helix involved in membrane association is shown. Membrane attachment is mediated by an interfacial binding surface on the N-terminal domain of the protein, which likely includes a cluster of basic residues and the adjacent exposed loop β3-α2. Protein-membrane interactions stimulate catalysis by facilitating substrate diffusion from the lipid bilayer to the catalytic site and/or by inducing allosteric changes in the protein. C, overall structure and proposed mode of action for LpqW. LpqW is predicted to be a monomeric membrane-associated lipoprotein composed of 600 amino acids (62.9 kDa). The crystal structure revealed that the protein is organized in two lobes. Three structural domains (I, II, and III) can be identified, with domains I (magenta) and II (orange) representing the "lower" lobe (lobe 1) and domain III (yellow) representing the "upper" lobe (lobe 2). Although the structure of LpqW was determined in the non-liganded state, the major periplasmic component of PIM₄ (t-α-Manp(1→6)-α-Manp(1→6)) was accommodated by using *in silico* docking. It is proposed that LpqW functions at the divergence point of the polar PIM and LM/LAM biosynthetic pathways to control the relative abundance of these species in the mycobacterial cell envelope.
that resembles those of a family of bacterial substrate-binding
proteins (42). A plausible model was suggested in which an
electronegative interdomain cavity in LpqW might bind the
Ac₁PIM₄ intermediate (Fig. 2C) to channel it into the LM/LAM
biosynthetic pathway, thus controlling the relative abundance
of higher PIMs and LM/LAM (Fig. 1B).

Compartmentalization of the PIM Biosynthetic Pathway
and Translocation of PIMs across the Cell Envelope

As evidenced by the nature of the GTs and sugar donors
involved and the asymmetrical PIM composition of the inner
and outer leaflets of the mycobacterial plasma membrane (43),
the biosynthesis of PIM, LM, and LAM is topologically com-
plex. Whereas the first two mannosylation steps of the pathway
at least involve GDP-Manp-dependent enzymes and occur on
the cytoplasmic face of the plasma membrane (22, 23, 38, 43),
further steps in the biosynthesis of the higher, more polar forms
of PIMs (PIM5 and PIM6 in their various acylated forms) and
metabolically related LM and LAM appear to rely upon integral
membrane GT-C-type GTs and to take place on the periplas-
mic side of the membrane (Fig. 1B) (7, 31, 43, 44).⁴ Thus, similar
to other M. tuberculosis glycolipids, such as sulfolipid-I and the
linker unit of the mycobacterial cell wall (for a recent review, see
Ref. 8), PIMs clearly display a compartmentalized biosynthetic
pathway organized around the inner and outer leaflets of the
plasma membrane. Such a compartmentalization implies the
translocation of PIM intermediates (i.e. PIM₂, PIM₃, and/or
PIM₄) from the cytoplasmic to the periplasmic side of the mem-
brane. Likewise, much like the lipid-linked oligosaccharides
involved in the biosynthesis of bacterial (lipo)polysaccharides
and peptidoglycan (45–47), it is expected that polyprenol-
phosphate-mannose is translocated to the periplasmic side of
the plasma membrane to serve as the Manp donor in the glyco-
syl transfer reactions catalyzed by PimE and subsequent GT-C-
type ManTs of the PIM, LM, and LAM pathway. Beyond the
plasma membrane, because two different populations of PIMs
(one associated with the inner membrane and the other associ-
ated with the outer membrane) have been described (2, 48),
transporters must exist that are responsible for their transloca-
tion across the periplasm and to the cell surface. None of the
transporters involved in these processes have yet been
identified.

Knowns and Unknowns of the Physiological Roles and
Biological Activities of PIMs

The role of PIMs in the physiology of mycobacteria remains
unclear. Because in *M. bovis* BCG PI and PIMs make up as
much as 56% of all phospholipids in the cell wall and 37% of
those in the plasma membrane, these molecules have long been
thought to be essential structural components of the mycobac-
terial cell envelope (48). Drug susceptibility testing and uptake
experiments with norfloxacin or chenodeoxycholate per-
formed on recombinant *M. smegmatis* and *M. tuberculosis*
strains affected in their polar or apolar PIM contents clearly
implicated these glycolipids in the permeability of the cell enve-
lope to both hydrophilic and hydrophobic molecules (22, 31,
49). Recent electron microscopy studies on a *pimE*-deficient
mutant of *M. smegmatis* further pointed to a role of higher

order PIMs in cell membrane integrity and in the regulation of
cell septation and division (31). Somewhat supporting these
observations, polar and apolar PIM production was reported to
be affected by environmental factors known to impact replica-
tion rate and/or membrane fluidity, such as carbon/nitrogen
sources and temperature (50, 51). The amount of higher order
PIMs (PIM<sub>5</sub> and PIM<sub>6</sub>) recovered from mycobacterial cells
increases with the age of the culture, probably at the expense of
the apolar forms (PIM<sub>1</sub>–PIM<sub>4</sub>), the synthesis of which was
shown to decrease in *M. smegmatis* when cultures enter sta-
tionary phase (43, 52, 53). The regulatory mechanisms involved
and the specific steps of the PIM pathway at which they act,
whether exclusively at the level of LpqW or otherwise, are not
known. Although higher order PIMs are dispensable molecules
in *M. smegmatis*, *M. bovis* BCG, and *M. tuberculosis* (31, 54),<sup>4</sup
such is not the case with PIM<sub>1</sub> and PIM<sub>2</sub>, the disruption of
which causes immediate growth arrest in both fast- and slow-
growing mycobacteria (22, 23). Interestingly, we found the dis-
ruption of the acyltransferase Rv2611c to be lethal to *M. tuber-
culosis* H37Rv and to result in severe growth defects in
*M. smegmatis* (25),<sup>4</sup> emphasizing the critical physiological
impact of not only the degree of mannosylation of PIMs but also
their acylation state.

Much of what is known of the roles of PIMs in host-pathogen
interactions is derived from *in vitro* studies using various cell
models and purified PIM molecules or whole mycobacterial
cells (for recent reviews, see Refs. 9 and 55–57). PIMs are major
non-peptidic antigens of the host innate and acquired immune
responses. They are TLR-2 agonists and stimulate unconven-
tional αβ T-lymphocytes in the context of CD1 proteins.
Importantly, PIMs are also recognized by the C-type lectins
mannose receptor, mannose-binding protein, and DC-SIGN
and, as such, play a role in the opsonic and non-opsonic binding
of *M. tuberculosis* to phagocytic and non-phagocytic cells. The
higher forms of PIMs in particular, which contain two α-1,2-
linked Manp residues, identical to the dimannoside motif dec-
orating the nonreducing termini of the arabinosyl side chains of
mannosylated LAM, have been shown to share with mannosy-
lated LAM the ability to engage the mannose and DC-SIGN
receptors of phagocytic cells and, in so doing, to impact phago-
some-lysosome fusion in cultured human monocyte-derived
macrophages (54, 58). Both the fatty acyl appendages of PIMs
and their degree of mannosylation are important to their inter-
actions with host cells. However, a better understanding of
their roles in the pathogenesis of tuberculosis would greatly
benefit from the availability of *M. tuberculosis* mutants defi-
cient in either their synthesis (wherever possible) or transport
to the cell surface.

**Concluding Remarks and Future Challenges**

Considerable advances have been made over the last 10 years
in understanding the genetics and biochemistry of PIM synthe-
sis in *M. tuberculosis*. Foremost among these advances has been
the structural characterization of PimA (in fact, the very first
crystal structure of a GT involved in mycobacterial cell wall
biosynthesis) and the proposal of a model for interpreting the
conformational changes and membrane interactions associated
with its catalytic mechanism. This model may represent a par-

<figure><img src="image_5.png" /></figure>
## MINIREVIEW: PIM Biosynthesis in Mycobacteria

adigm for other cytosolic bacterial cell wall biosynthetic enzymes working at the interface with the plasma membrane. Our current knowledge of the molecular mechanisms of substrate/membrane recognition by PimA and PimB' in turn places us in an unprecedented position to identify inhibitors of these enzymes and to develop new drugs with bactericidal mechanisms different from those of presently available agents. Yet considerable challenges remain to be overcome to fully understand the biosynthetic machinery of PIMs, their translocation to the cell surface, their roles in the physiology of mycobacteria, and their contribution to host-pathogen interactions. Among the biochemistry challenges are (i) the identification of the third and fourth α-1,6-ManTs of the pathway (PimC and PimD), that of the α-1,2-ManT catalyzing the formation of PIM₆ from PIM₅, and that of the acyltransferase responsible for the acylation of position 3 of *myo*-inositol; (ii) the elucidation of the transport machinery responsible for the translocation of PIM intermediates and lipid-linked sugars across the inner membrane and for the transport of the presumably fully assembled higher and lower forms of PIMs to the cell surface; (iii) the elucidation of the crystal structure of PIM biosynthetic enzymes in complex with PI or PIMs; and (iv) the discovery of potent inhibitors of the PIM pathway that would not only provide bases for the rational design of novel drugs targeting *M. tuberculosis* but also be useful to probe the physiological functions of PIM, LM, and LAM during *in vitro* growth and in the course of host infection.

## REFERENCES

1. Anderson, R. J. (1930) *J. Am. Chem. Soc.* **52**, 1607–1608

2. Ballou, C. E., Vilkas, E., and Lederer, E. (1963) *J. Biol. Chem.* **238**, 69–76

3. Lee, Y. C., and Ballou, C. E. (1964) *J. Biol. Chem.* **239**, 1316–1327

4. Brennan, P. J. (1988) in *Microbial Lipids* (Ratledge, C., and Wilkinson, S. G., eds) pp. 203–298, Academic Press Ltd., London

5. Ortalo-Magné, A., Lemassu, A., Lanéelle, M. A., Bardou, F., Silve, G., Gounon, P., Marchal, G., and Daffé, M. (1996) *J. Bacteriol.* **178**, 456–461

6. Pitarque, S., Larrouy-Maumus, G., Payré, B., Jackson, M., Puzo, G., and Nigou, J. (2008) *Tuberculosis* **88**, 560–565

7. Berg, S., Kaur, D., Jackson, M., and Brennan, P. J. (2007) *Glycobiology* **17**, 35–56R. Review.

8. Kaur, D., Guerin, M. E., Skovierová, H., Brennan, P. J., and Jackson, M. (2009) *Adv. Appl. Microbiol.* **69**, 23–78

9. Gilleron, M., Jackson, M., Nigou, J., and Puzo, G. (2008) in *The Mycobacterial Cell Envelope* (Daffé, M., and Reyrat, J. M., eds) pp. 75–105, American Society for Microbiology, Washington, D.C.

10. Gilleron, M., Quesniaux, V. F., and Puzo, G. (2003) *J. Biol. Chem.* **278**, 29880–29889

11. Anderson, R. J., and Renfrew, A. G. (1930) *J. Am. Chem. Soc.* **52**, 1252–1254

12. Anderson, R. J., and Roberts, G. (1930) *J. Am. Chem. Soc.* **52**, 5023–5029

13. Anderson, R. J. (1939) *Prog. Chem. Org. Nat. Prod.* **3**, 145–202

14. Lee, Y. C., and Ballou, C. E. (1965) *Biochemistry* **4**, 1395–1404

15. Hill, D. L., and Ballou, C. E. (1966) *J. Biol. Chem.* **241**, 895–902

16. Chatterjee, D., Hunter, S. W., McNeil, M., and Brennan, P. J. (1992) *J. Biol. Chem.* **267**, 6228–6233

17. Gilleron, M., Ronet, C., Mempel, M., Monsarrat, B., Gachelin, G., and Puzo, G. (2001) *J. Biol. Chem.* **276**, 34896–34904

18. Brennan, P., and Ballou, C. E. (1967) *J. Biol. Chem.* **242**, 3046–3056

19. Hunter, S. W., and Brennan, P. J. (1990) *J. Biol. Chem.* **265**, 9272–9279

20. Khoo, K. H., Dell, A., Morris, H. R., Brennan, P. J., and Chatterjee, D. (1995) *Glycobiology* **5**, 117–127

21. Nigou, J., Gilleron, M., Cahuzac, B., Bounéry, J. D., Herold, M., Thurnher, M., and Puzo, G. (1997) *J. Biol. Chem.* **272**, 23094–23103

22. Korduláková, J., Gilleron, M., Mikusova, K., Puzo, G., Brennan, P. J., Gicquel, B., and Jackson, M. (2002) *J. Biol. Chem.* **277**, 31335–31344

23. Guerin, M. E., Kaur, D., Somashekar, B. S., Gibbs, S., Gest, P., Chatterjee, D., Brennan, P. J., and Jackson, M. (2009) *J. Biol. Chem.* **284**, 25687–25696

24. Lea-Smith D. J., Martin, K. L., Pyke, J. S., Tull, D., McConville, M. J., Coppel, R. L., and Crellin, P. K. (2008) *J. Biol. Chem.* **283**, 6773–6782

25. Korduláková, J., Gilleron, M., Puzo, G., Brennan, P. J., Gicquel, B., Mikusová, K., and Jackson, M. (2003) *J. Biol. Chem.* **278**, 36285–36295

26. Guerin, M. E., Kordulakova, J., Schaeffer, F., Svetlikova, Z., Buschiazzo, A., Giganti, D., Gicquel, B., Mikusova, K., Jackson, M., and Alzari, P. M. (2007) *J. Biol. Chem.* **282**, 20705–20714

27. Lairson, L. L., Henrissat, B., Davies, G. J., and Withers, S. G. (2008) *Annu. Rev. Biochem.* **77**, 521–555

28. Guerin, M. E., Schaeffer, F., Chaffotte, A., Gest, P., Giganti, D., Korduláková, J., van der Woerd, M., Jackson, M., and Alzari, P. M. (2009) *J. Biol. Chem.* **284**, 21613–21625

29. Chen, L., Men, H., Ha, S., Ye, X. Y., Brunner, L., Hu, Y., and Walker, S. (2002) *Biochemistry* **41**, 6824–6833

30. Varki, A., Cummings, R., Esko, J., Freeze, H., Stanley, P., Bertozzi, C. R., Hart, G., and Etzler, M. E. (2009) *Essentials of Glycobiology*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

31. Morita, Y. S., Sena, C. B., Waller, R. F., Kurokawa, K., Sernee, M. F., Nakatani, F., Haites, R. E., Billman-Jacobe, H., McConville, M. J., Maeda, Y., and Kinoshita, T. (2006) *J. Biol. Chem.* **281**, 25143–25155

32. Lind, J., Rämö, T., Klement, M. L., Bárány-Wallje, E., Epand, R. M., Epand, R. F., Måler, L., and Wieslander, A. (2007) *Biochemistry* **46**, 5664–5677

33. Wang, X., Weldeghiorthis, T., Zhang, G., Imperiali, B., and Prestegard, J. H. (2008) *Structure* **16**, 965–975

34. Seelig, J. (2004) *Biochim. Biophys. Acta* **1666**, 40–50

35. Wieprecht, T., Apostolov, O., Beyermann, M., and Seelig, J. (2000) *Biochemistry* **39**, 191–201

36. Kremer, L., Gurcha, S. S., Bifani, P., Hitchen, P. G., Baulard, A., Morris, H. R., Dell, A., Brennan, P. J., and Besra, G. S. (2002) *Biochem. J.* **363**, 437–447

37. Patterson, J. H., Waller, R. F., Jeevarajah, D., Billman-Jacobe, H., and McConville, M. J. (2003) *Biochem. J.* **372**, 77–86

38. Morita, Y. S., Patterson, J. H., Billman-Jacobe, H., and McConville, M. J. (2004) *Biochem. J.* **378**, 589–597

39. Kovacevic, S., Anderson, D., Morita, Y. S., Patterson, J., Haites, R., McMillan, B. N., Coppel, R., McConville, M. J., and Billman-Jacobe, H. (2006) *J. Biol. Chem.* **281**, 9011–9017

40. Crellin, P. K., Kovacevic, S., Martin, K. L., Brammananth, R., Morita, Y. S., Billman-Jacobe, H., McConville, M. J., and Coppel, R. L. (2008) *J. Bacteriol.* **190**, 3690–3699

41. Marland, Z., Beddoe, T., Zaker-Tabrizi, L., Lucet, I. S., Brammananth, R., Whisstock, J. C., Wilce, M. C., Coppel, R. L., Crellin, P. K., and Rossjohn, J. (2006) *J. Mol. Biol.* **359**, 983–997

42. Tam, R., and Saier, M. H., Jr. (1993) *Microbiol. Rev.* **57**, 320–346

43. Morita, Y. S., Velasquez, R., Taig, E., Waller, R. F., Patterson, J. H., Tull, D., Williams, S. J., Billman-Jacobe, H., and McConville, M. J. (2005) *J. Biol. Chem.* **280**, 21645–21652

44. Besra, G. S., Morehouse, C. B., Rittner, C. M., Waechter, C. J., and Brennan, P. J. (1997) *J. Biol. Chem.* **272**, 18460–18466

45. Raetz, C. R., and Whitfield, C. (2002) *Annu. Rev. Biochem.* **71**, 635–700

46. Ruiz, N. (2008) *Proc. Natl. Acad. Sci. U.S.A.* **105**, 15553–15557

47. Bos, M. P., Robert, V., and Tommassen, J. (2007) *Annu. Rev. Microbiol.* **61**, 191–214

48. Goren, M. B. (1984) in *The Mycobacteria: A Sourcebook* (Kubica, G. P., and Wayne, L. G., eds) Vol. 1, pp. 379–415, Marcel Dekker, Inc., New York

49. Parish, T., Liu, J., Nikaido, H., and Stoker, N. G. (1997) *J. Bacteriol.* **179**, 7827–7833

50. Dhariwal, K. R., Chander, A., and Venkitasubramanian, T. A. (1977) *Can. J. Microbiol.* **23**, 7–19

51. Taneja, R., Malik, U., and Khuller, G. K. (1979) *J. Gen. Microbiol.* **113**, 413–416

52. Penumarti, N., and Khuller, G. K. (1983) *Experientia* **39**, 882–884

53. Haites, R. E., Morita, Y. S., McConville, M. J., and Billman-Jacobe, H. (2005) *J. Biol. Chem.* **280**, 10981–10987
MINIREVIEW: PIM Biosynthesis in Mycobacteria

54. Driessen, N. N., Ummels, R., Maaskant, J. J., Gurcha, S. S., Besra, G. S., Ainge, G. D., Larsen, D. S., Painter, G. F., Vandenbroucke-Grauls, C. M., Geurtsen, J., and Appelmelk, B. J. (2009) *Infect. Immun.* **77**, 4538–4547

55. Briken, V., Porcelli, S. A., Besra, G. S., and Kremer, L. (2004) *Mol. Micro-biol.* **53**, 391–403

56. Fenton, M. J., Riley, L. W., and Schlesinger, L. S. (2005). in *Tuberculosis*

and the *Tubercle Bacillus* (Cole, S. T., Davis Eisenach, K., McMurray, D. N., and Jacobs, W. R., Jr., eds.) pp. 405–426, American Society for Microbiology, Washington, D.C.

57. Torrelles, J. B., and Schlesinger, L. S. (2010) *Tuberculosis* **90**, 84–93

58. Torrelles, J. B., Azad, A. K., and Schlesinger, L. S. (2006) *J. Immunol.* **177**, 1805–1816.

<figure><img src="image_6.png" /></figure>